News

A new study found patients with HS are significantly more likely to develop new-onset depression and anxiety, regardless of disease severity.

This session was titled ‘The Hidden Undercurrent: When Hair Loss Isn’t Alopecia Areata’ and was presented at the DERM 2025 conference by April Armstrong, MD, MPH.

Topline results from the first of 2 studies in the UP-AA program show upadacitinib 15 mg and 30 mg met the primary endpoint for scalp hair coverage.

In her DERM 2025 conference interview, Martinez-Dulay highlights takeaways from her sessions on atopic dermatitis, prurigo nodularis, and lymphoma.

A randomized trial found pharmacist-led counseling improved allergic rhinitis symptom control but did not enhance adherence, knowledge, or quality of life.

Findings suggest 7000 steps per day is associated with a reduced risk of health outcomes including mortality, cardiovascular disease, and type 2 diabetes.

New data revealed that sleep impairment, especially daytime dysfunction, short duration, and sleep disturbances, is linked to increased diabetes distress.

Study findings suggest significant sex disparities in liver complication risk among adult patients with cirrhosis, especially in the context of nonviral cirrhosis.

Bercik reviews study findings suggesting gluten restriction is not necessary for most patients with IBS, citing its apparent lack of impact on symptoms.

Phase 4 trial shows esketamine provides significant symptom relief in patients with treatment-resistant depression within 24 hours of the first dose.

Experts discuss the evolving management of asthma and COPD.

The unsaturated fats from vegetable oils reduce inflammation and influence organ metabolism, resulting in lowered ALT, AST, and TBIL indexes.

Patients and clinicians perceived a gap that largely didn't exist in views on diet's role in IBD.

FDA approves pegcetacoplan (Empaveli) for treating C3 glomerulopathy and primary IC-MPGN, offering hope for patients aged 12 and older.

Elkady joins the program to discuss her experience transitioning from patient care to clinical trials and industry.

A multidisciplinary care program achieved a 95% cure rate with Sofosbuvir/Velpatasvir therapy.

Deming explains drivers of new infections, systemic barriers impeding progress, and the changes she believes are needed to aid elimination efforts.

This interview with Cotter highlights his session on the use of AI tools in the dermatology field.

Sands describes the current landscape of Crohn’s disease therapies and reviews GALAXI 2 and 3 data supporting guselkumab’s role in evolving care paradigms.

Anti-TNF therapies show strong 3-year durability in pediatric IBD, with new clinical markers helping predict early nonresponse in Crohn’s disease and UC/IBD-unclassified cases.

A study investigating frequently used treatments, mean duration from first symptom to index date, and disease phenotypes found most cases are mild to moderate.

This interview with Hure covers 2 of her sessions at DERM 2025, including a discussion of microplastics and forever chemicals, as well as the skin’s microbiome.

The approval was based on positive results from the phase 3 foresiGHt trial and expands upon the indication for pediatric growth hormone deficiency.

A new study highlights stress, concussion, and other early-life factors as key contributors to pediatric pain-predominant DGBIs.

Swanson speaks in this interview segment about her DERM 2025 session on speaking with parents and their children or teens as a clinician.

This interim data was drawn from the TRACE study, highlighting real-world use of tralokinumab in adults with atopic dermatitis of the head and neck.

In this interview, Swanson highlights her DERM 2025 session ‘Systemic Therapy for the Pediatric Acne Patient’ and its takeaways.

In this DERM2025 interview, Friedman highlighted some of the discussion points from his presentation on off-label strategies for therapeutic challenges.